Insight: Binding of bromocresol green and bromocresol purple to album

About the Authors and Research Background

This study was conducted by a clinical biochemistry team at Ghent University Hospital in Belgium. The lead author, Joris Delanghe, specializes in metabolic analysis in kidney disease; co-author Sigurd Delanghe holds an h-index of 10 with 336 cumulative citations, reflecting broader influence in protein binding analysis and clinical laboratory methodology; Sunny Eloot contributes expertise in hemodialysis efficiency quantification through the Kt/V parameter. Published in 2017 and cited 21 times to date—including one high-impact citation—the study asks a focused question: why do bromocresol purple (BCP) and bromocresol green (BCG), two standard colorimetric albumin assay methods, yield systematically different results in chronic kidney disease patients, and what drives this divergence?

The research methodology is rigorous: 62 serum specimens from hemodialysis patients were analyzed simultaneously by immunonephelometry (the gold standard), BCP colorimetry, and BCG colorimetry. Uremic toxins were quantified via high-performance liquid chromatography, and acute phase proteins including C-reactive protein and α1-acid glycoprotein were assessed nephelometrically. This multi-method, multi-variable cross-validation design is precisely what earned the study its high-impact citation and makes it methodologically relevant far beyond its clinical context.

Core Findings: Multiple Hidden Factors Systematically Distort Albumin Measurement

The study's central finding challenges a widely held assumption in clinical laboratories: that BCP and BCG methods are interchangeable. In uremic patients, the BCP/BCG ratio is not a fixed constant but a dynamic variable shaped by multiple interacting factors.

Finding One: Para-Cresyl Sulfate Positively Elevates the BCP/BCG Ratio

Among the uremic toxins investigated, total para-cresyl sulfate (PCS) showed a significant positive correlation with the BCP/BCG ratio. As PCS accumulates with declining kidney function, BCP-measured albumin values become systematically elevated relative to BCG values. Clinicians relying solely on BCP data may underestimate the severity of malnutrition in these patients, potentially delaying intervention. The key lesson: a measurement tool that appears to function correctly in healthy populations may introduce systematic bias in a specific risk group.

Finding Two: α1-Acid Glycoprotein and Dialysis Efficiency Inversely Correlate with the Ratio

The acute phase protein α1-acid glycoprotein showed a negative correlation with the BCP/BCG ratio, as did the Kt/V parameter representing dialysis adequacy. This means that more effective dialysis treatment and more active inflammatory response actually widen the gap between the two measurement methods. No single indicator captures this multi-factor dynamic; reliable clinical judgment requires simultaneous monitoring of multiple dimensions. The 62-sample multivariate analysis in this study clearly demonstrates the value of cross-validated data over single-metric reliance.

BCM Implications for Taiwan Enterprises: Measurement Reliability Is the Foundation of BCP

The most direct BCM implication of this research is that systematic measurement bias—not random error—is the more dangerous threat to decision quality. Random errors tend to average out; systematic biases compound over time and lead entire organizations to optimize for the wrong targets. Taiwan enterprises building BCP frameworks under ISO 22301 face an identical structural risk.

Dimension One: The Data Foundation of RTO and RPO Settings. Many Taiwan enterprises conduct Business Impact Analysis (BIA) using system availability data and service interruption histories drawn from different departmental systems with different definitional standards. Just as BCP and BCG each have internally logical methodologies that nevertheless diverge systematically when cross-validated, IT departments, operations teams, and finance departments often apply different start-point definitions to "service interruption time." This information asymmetry means RTO targets may lack an executable basis from the moment they are established.

Dimension Two: The Necessity of Multi-Indicator Cross-Validation. The research team used immunonephelometry as an independent gold standard while simultaneously comparing two colorimetric methods and incorporating PCS, α1-acid glycoprotein, and Kt/V as cross-validation variables. This design logic maps directly to ISO 22301 Clause 9 performance evaluation requirements: a single KPI cannot reflect the full picture of organizational resilience. Taiwan enterprises should build monitoring frameworks that integrate technical indicators (system availability, round-trip time), process indicators (critical function recovery time), and human factors (drill performance scores) to ensure BCM effectiveness assessments remain free from measurement distortion.

Dimension Three: Institutionalized Baseline Recalibration. The study's confounding factors—PCS levels, inflammatory proteins, Kt/V—are not static; they evolve dynamically with patient condition. Similarly, Taiwan enterprises' business environments—supply chain structures, IT architectures, key personnel compositions—are in continuous evolution. This is precisely why ISO 22301 mandates annual management reviews and immediate BCP updates following significant organizational changes. Treating baseline recalibration as a continuous institutional obligation rather than a one-time initialization step is the deepest methodological contribution this research makes to BCM practice.

How Winners Consulting Services Helps Taiwan Enterprises Build Reliable BCM Data Foundations

Winners Consulting Services Co. Ltd. (積穗科研股份有限公司) assists Taiwan enterprises in establishing BCP frameworks aligned with ISO 22301, setting defensible RTO/RPO targets, conducting Business Impact Analysis (BIA), and executing crisis management drills. Drawing on the measurement reliability insights of this research, we recommend the following concrete action steps:

1. BIA Data Consistency Audit: Before initiating or renewing ISO 22301 certification, audit all departmental data sources and definitional standards for service interruption records. Eliminate cross-departmental information asymmetry and designate a single authoritative data source as the calibration baseline for all BCM indicators—just as this study used immunonephelometry as its independent gold standard.
2. Multi-Dimensional Performance Monitoring Dashboard: In accordance with ISO 22301 Clause 9.1 requirements for monitoring, measurement, analysis, and evaluation, design a three-tier indicator system covering technical (system availability, RTT monitoring), process (critical business function recovery time), and human (drill qualification rates) dimensions, to prevent single-metric blind spots from distorting organizational resilience assessments.
3. Semi-Annual Baseline Recalibration Protocol: Referencing the dynamic correlation between Kt/V and BCP/BCG ratio demonstrated in this study, establish a semi-annual BIA data recalibration and RTO/RPO reasonableness review in the enterprise BCM calendar. Designate supply chain restructuring, IT architecture upgrades, or key personnel changes as automatic triggers for interim recalibration, ensuring BCP continuously reflects actual organizational resilience rather than an outdated snapshot.

Frequently Asked Questions

What is the most common data quality mistake Taiwan enterprises make when setting RTO and RPO targets?

The most prevalent error is cross-departmental definitional inconsistency in recording service interruption events. IT teams typically start the clock at alert trigger, while operations teams record impact onset—a gap that can range from 15 to 45 minutes per incident. Accumulated across a year of historical data, this systematic offset can render RTO baseline figures unreliable. This mirrors the BCP/BCG divergence in the Delanghe et al. study: both methods follow internally valid logic, yet yield systematically different results when applied to the same underlying reality. The solution is to mandate a cross-functional data definition dictionary before any BIA process begins under ISO 22301, and to designate a single authoritative data source as the calibration anchor for all BCM metrics.

What are the most common ISO 22301 compliance challenges for Taiwan enterprises?

Based on Winners Consulting's advisory experience, Taiwan enterprises most frequently struggle with two specific requirements. First, the Business Impact Analysis (BIA) required under ISO 22301 Clause 8.2 often lacks quantitative foundation—many organizations rely on subjective scoring rather than historical data. Second, BCP exercises required under Clause 8.4 tend to be procedural rather than genuinely testing RTO achievability. Additionally, management review obligations under Clause 9.3 are frequently treated as annual checkbox exercises rather than as calibration opportunities. Medium-sized Taiwan enterprises in particular tend to underinvest in the data governance infrastructure that makes ISO 22301 compliance functionally meaningful rather than documentarily complete.

What is the standard timeline and process for implementing ISO 22301?

A structured ISO 22301 implementation typically spans four phases: Phase 1, current-state diagnostic and gap analysis (4–6 weeks), assessing the distance between existing mechanisms and standard requirements; Phase 2, framework design and documentation (8–12 weeks), covering BIA, risk assessment, and the BCP document system; Phase 3, implementation and personnel training (6–8 weeks), including tabletop exercises and live scenario testing; Phase 4, internal audit and certification review (4–6 weeks). Total implementation duration ranges from 7 to 12 months depending on organizational scale and existing capabilities. The quality of data inputs at each phase directly determines the reliability of outputs in subsequent phases—a principle this study's multi-stage validation methodology illustrates with precision.

How should Taiwan enterprises assess the cost-benefit case for ISO 22301 investment?

ISO 22301 implementation costs vary significantly by enterprise scale, but the benefit case rests on two quantifiable dimensions. First, risk reduction: research indicates approximately 40% of total business interruption losses derive from customer attrition and contract penalty clauses rather than direct IT remediation costs; enterprises with comprehensive BCP frameworks typically achieve 60% or greater reduction in mean recovery time following disruption events. Second, commercial positioning: a growing number of Taiwan's large enterprises and multinational customers now require ISO 22301 certification as a procurement prerequisite, particularly in financial services, semiconductors, and medical devices. Winners Consulting recommends structuring the ROI analysis as (potential interruption loss × probability of occurrence) versus implementation cost, rather than treating ISO 22301 as a pure administrative compliance expenditure.

Why should Taiwan enterprises choose Winners Consulting Services for BCM advisory?

Winners Consulting Services Co. Ltd. (積穗科研股份有限公司) brings multi-industry ISO 22301 implementation experience spanning financial services, manufacturing, technology, and healthcare sectors in Taiwan. Our differentiated value lies in addressing BCM from the data governance foundation rather than stopping at documentation compliance. We apply validated BIA methodologies that enable enterprises to set quantitatively defensible RTO/RPO targets, build multi-dimensional performance monitoring systems, and establish recalibration protocols that keep ISO 22301 frameworks continuously aligned with actual organizational structure. Our complimentary BCM diagnostic service allows enterprises to clearly understand their compliance gaps and improvement priorities before committing resources—ensuring that every investment in ISO 22301 translates into genuine organizational resilience rather than certification-only outcomes.

積穗科研股份有限公司（Winners Consulting Services Co. Ltd.）は、2017年にベルギーのゲント大学病院の臨床化学チームが発表した血液透析患者のアルブミン測定に関する研究から、業務継続管理（BCM）の実務に直結する重要な方法論的洞察を引き出しています。測定ツール自体に系統的偏差が存在する場合、その測定値に基づく全ての意思決定の信頼性が根底から崩壊する——この医学的発見は、ISO 22301に基づくBCP（業務継続計画）の構築において、RTO/RPO設定のデータ基盤の信頼性がいかに重要であるかを改めて問い直します。